Skip to main content
SpringerLink
Log in

Soluble Epidermal Growth Factor Receptor: A Biomarker of Epithelial Ovarian Cancer

  • Chapter
  • First Online:
Ovarian Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 149))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem. 1993;62:453–481.

    CAS  PubMed  Google Scholar 

  2. Peles E, Yarden Y. Neu and its ligands: from an oncogene to neural factors. Bioessays. 1993;15(12):815–824.

    Article  CAS  PubMed  Google Scholar 

  3. Maihle NJ, Baron AT, Barrette BA, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002;107:247–258.

    CAS  PubMed  Google Scholar 

  4. Yarden Y, Ullrich A. Molecular analysis of signal transduction by growth factors. Biochemistry. 1988;27(9):3113–3119.

    Article  CAS  PubMed  Google Scholar 

  5. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science. 1991;252(5006):668–674.

    Article  CAS  PubMed  Google Scholar 

  6. Kavanaugh WM, Williams LT. An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science. 1994;266(5192):1862–1865.

    Article  CAS  PubMed  Google Scholar 

  7. Adamson ED. EGF receptor activities in mammalian development. Mol Reprod Dev. 1990;27(1):16–22.

    Article  CAS  PubMed  Google Scholar 

  8. Wiley LM, Adamson ED, Tsark EC. Epidermal growth factor receptor function in early mammalian development. Bioessays. 1995;17(10):839–846.

    Article  CAS  PubMed  Google Scholar 

  9. Petch LA, Harris J, Raymond VW, Blasband A, Lee DC, Earp HS. A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue. Mol Cell Biol. 1990;10(6):2973–2982.

    CAS  PubMed  Google Scholar 

  10. Das SK, Tsukamura H, Paria BC, Andrews GK, Dey SK. Differential expression of epidermal growth factor receptor (EGF-R) gene and regulation of EGF-R bioactivity by progesterone and estrogen in the adult mouse uterus. Endocrinology. 1994;134:971–981.

    Article  CAS  PubMed  Google Scholar 

  11. Tong BJ, Das SK, Threadgill D, Magnuson T, Dey SK. Differential expression of the full-length and truncated forms of the epidermal growth factor receptor in the preimplantation mouse uterus and blastocyst. Endocrinology. 1996;137:1492–1496.

    Article  CAS  PubMed  Google Scholar 

  12. Reiter JL, Threadgill DW, Eley GD, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 2001;71(1):1–20.

    Article  CAS  PubMed  Google Scholar 

  13. Maihle NJ, Flickinger TW, Raines MA, Sanders ML, Kung HJ. Native avian c-erbB gene expresses a secreted protein product corresponding to the ligand-binding domain of the receptor. Proc Natl Acad Sci U S A. 1991;88(5):1825–1829.

    Article  CAS  PubMed  Google Scholar 

  14. Reiter JL, Maihle NJ. A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res. 1996;24(20):4050–4056.

    Article  CAS  PubMed  Google Scholar 

  15. Ilekis J, Stark BC, Benveniste R. Expression of Epidermal Growth Factor Receptors at the mRNA and Cell Membrane Levels in First Trimester and Term Human Placentae. New York: Plenum; 1991.

    Google Scholar 

  16. Ilekis JV, Stark BC, Scoccia B. Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta. Mol Reprod Dev. 1995;41(2):149–156.

    Article  CAS  PubMed  Google Scholar 

  17. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–425.

    Article  CAS  PubMed  Google Scholar 

  18. Merlino GT, Ishii S, Whang-Peng J, et al. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol. 1985;5(7):1722–1734.

    CAS  PubMed  Google Scholar 

  19. Lin CR, Chen WS, Kruiger W, et al. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science. 1984;224(4651):843–848.

    Article  CAS  PubMed  Google Scholar 

  20. Weber W, Gill GN, Spiess J. Production of an epidermal growth factor receptor-related protein. Science. 1984;224(4646):294–297.

    Article  CAS  PubMed  Google Scholar 

  21. Xu YH, Richert N, Ito S, Merlino GT, Pastan I. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A. 1984;81(23):7308–7312.

    Article  CAS  PubMed  Google Scholar 

  22. Reiter JL, Maihle NJ. Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta. Ann N Y Acad Sci. 2003;995:39–47.

    Article  CAS  PubMed  Google Scholar 

  23. Baron AT, Lafky JM, Connolly DC, et al. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. J Immunol Methods. 1998;219(1–2):23–43.

    Article  CAS  PubMed  Google Scholar 

  24. Baron AT, Lafky JM, Boardman CH, et al. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(2):129–137.

    CAS  PubMed  Google Scholar 

  25. Baron AT, Lafky JM, Suman VJ, et al. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev. 2001;10(11):1175–1185.

    CAS  PubMed  Google Scholar 

  26. Baron AT, Cora EM, Lafky JM, et al. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(2):103–113.

    CAS  PubMed  Google Scholar 

  27. Baron AT, Boardman CH, Lafky JM, et al. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:306–318.

    Google Scholar 

  28. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994;300:281–290.

    CAS  PubMed  Google Scholar 

  29. Cadena DL, Gill GN. Expression and purification of the epidermal growth factor receptor extracellular domain utilizing a polycistronic expression system. Protein Expr Purif. 1993;4(3):177–186.

    Article  CAS  PubMed  Google Scholar 

  30. Greenfield C, Hiles I, Waterfield MD, et al. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J. 1989;8(13):4115–4123.

    CAS  PubMed  Google Scholar 

  31. Hurwitz DR, Emanuel SL, Nathan MH, et al. EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. J Biol Chem. 1991;266(32):22035–22043.

    CAS  PubMed  Google Scholar 

  32. Lax I, Burgess WH, Bellot F, Ullrich A, Schlessinger J, Givol D. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol. 1988;8(4):1831–1834.

    CAS  PubMed  Google Scholar 

  33. Wu D, Wang L, Chi Y, Sato GH, Sato JD. Human epidermal growth factor receptor residue covalently cross-linked to epidermal growth factor receptor. Proc Natl Acad Sci U S A. 1990;87:3151–3155.

    Article  CAS  PubMed  Google Scholar 

  34. Basu A, Raghunath M, Bishayee S, Das M. Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol Cell Biol. 1989;9(2):671–677.

    CAS  PubMed  Google Scholar 

  35. Ilekis JV, Gariti J, Niederberger C, Scoccia B. Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer. Gynecol Oncol. 1997;65(1):36–41.

    Article  CAS  PubMed  Google Scholar 

  36. Flickinger TW, Maihle NJ, Kung HJ. An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation. Mol Cell Biol. 1992;12(2):883–893.

    CAS  PubMed  Google Scholar 

  37. Granai CO, Gajewski WH, Arena B. Ovarian cancer: issues and management. Cancer J. 1994;7(1):7–11.

    Google Scholar 

  38. Harlap S. The epidemiology of ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the Ovary. New York: Raven Press, Ltd.; 1993:79–93.

    Google Scholar 

  39. Look KY. Evolution of screening for epithelial ovarian carcinoma: the quest for early diagnosis. Semin Surg Oncol. 1994;10(4):261–267.

    Article  CAS  PubMed  Google Scholar 

  40. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.

    Article  PubMed  Google Scholar 

  41. Ries LAG, Miller BA, Hankey BF. SEER Cancer Statistics Review, 1973–1991. Bethesda, MD: National Cancer Institute; 1997. Report No.: NIH Publ. No. 94-2789.

    Google Scholar 

  42. Hartge P, Whittemore AS, Itnyre J, McGowan L, Cramer D. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. Obstet Gynecol. 1994;84(5):760–764.

    CAS  PubMed  Google Scholar 

  43. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19(1):3–10.

    Article  CAS  PubMed  Google Scholar 

  44. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology. 1998;12(3):399–406; discussion 9–10, 13.

    CAS  PubMed  Google Scholar 

  45. Easton DF, Ford D, Bishop DT, Consortium BCL. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995;56(1):265–271.

    CAS  PubMed  Google Scholar 

  46. Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 1995;76(2):284–290.

    Article  CAS  PubMed  Google Scholar 

  47. Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives – findings in a large cohort study. Br J Cancer. 1995;71(6):1340–1342.

    CAS  PubMed  Google Scholar 

  48. Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol. 1988;128(6):1228–1240.

    CAS  PubMed  Google Scholar 

  49. Doraiswamy V, Parrott JA, Skinner MK. Expression and action of transforming growth factor alpha in normal ovarian surface epithelium and ovarian cancer. Biol Reprod. 2000;63(3):789–796.

    Article  CAS  PubMed  Google Scholar 

  50. Berchuck A, Rodriguez GC, Kamel A, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol. 1991;164(2):669–674.

    CAS  PubMed  Google Scholar 

  51. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991;47(1):87–98.

    CAS  PubMed  Google Scholar 

  52. Scambia G, Benedetti Panici P, Battaglia F, et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol. 1992;10(4):529–535.

    CAS  PubMed  Google Scholar 

  53. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183–232.

    Article  CAS  PubMed  Google Scholar 

  54. King CR, Kraus MH, DiFiore PP, Paik S, Kasprzyk PG. Implications of erbB-2 overexpression for basic science and clinical medicine. Semin Cancer Biol. 1990;1(5):329–337.

    CAS  PubMed  Google Scholar 

  55. Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res. 1987;47:707–712.

    CAS  PubMed  Google Scholar 

  56. Ridderheim M, Andersson A, Cajander S, Tribukait B, Stendahl U, Backstrom T. Release of epidermal growth factor/transforming growth factor alpha by ovarian tumours in vitro. Int J Oncol. 1994;5:781–786.

    Google Scholar 

  57. Karlan BY, Platt LD. Ovarian cancer screening. The role of ultrasound in early detection. Cancer. 1995;76(10 Suppl):2011–2015.

    Article  CAS  PubMed  Google Scholar 

  58. Schwartz PE, Chambers JT, Taylor KJ. Early detection and screening for ovarian cancer. J Cell Biochem. 1995;(Suppl 23):233–237.

    Google Scholar 

  59. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89(10):2068–2075.

    Article  CAS  PubMed  Google Scholar 

  60. Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76(10 Suppl):2092–2096.

    Article  CAS  PubMed  Google Scholar 

  61. Ruddon RW. Causes of cancer. In: Ruddon RW, ed. Cancer Biology. 3rd ed. New York: Oxford University Press; 1995:231–276.

    Google Scholar 

  62. Ozols RF, Rubin SC, Thomas G, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1997:919–986.

    Google Scholar 

  63. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol. 2001;127(2):73–79.

    Article  CAS  PubMed  Google Scholar 

  64. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990;322(15):1021–1027.

    Article  CAS  PubMed  Google Scholar 

  65. Wadler S. New developments in the treatment of ovarian cancer. Expert Opin Investig Drugs. 2001;10(6):1167–1172.

    Article  CAS  PubMed  Google Scholar 

  66. Kaye SB. Future directions for the management of ovarian cancer. Eur J Cancer. 2001;37(Suppl 9):S19–S23.

    Article  CAS  PubMed  Google Scholar 

  67. Oriel KA, Hartenbach EM, Remington PL. Trends in United States ovarian cancer mortality, 1979–1995. Obstet Gynecol. 1999;93(1):30–33.

    Article  CAS  PubMed  Google Scholar 

  68. Meden H, Marx D, Rath W, et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol. 1994;13(1):45–53.

    Article  CAS  PubMed  Google Scholar 

  69. Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol. 1997;71(2):173–179.

    Article  CAS  PubMed  Google Scholar 

  70. Meden H, Marx D, Schauer A, Wuttke W, Kuhn W. Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. Anticancer Res. 1997;17(1B):757–760.

    CAS  PubMed  Google Scholar 

  71. Cheung TH, Wong YF, Chung TKH, Maimonis P, Chang AMZ. Clinical use of serum c-erbB-2 in patients with ovarian masses. Gynecol Obstet Invest. 1999;48(2):133–137.

    Article  CAS  PubMed  Google Scholar 

  72. Yazici H, Dolapcioglu K, Buyru F, Dalay N. Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients. Cancer Investig. 2000;18(2):110–114.

    Article  CAS  Google Scholar 

  73. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I–II) epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001;11(2):119–129.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Oncology, Blood and Marrow Transplantation, Department of Internal Medicine, Lucille P. Markey Cancer Center, University of Kentucky, 408 Ben F. Roach Building, 800 Rose Street, 40536-0093, Lexington, KY, USA

    Andre T. Baron

  2. Tumor Biology Program, Mayo Clinic–Rochester, 55905, 200 First Street S.W., Rochester, MN, USA

    Jacqueline M. Lafky

  3. Department of Obstetrics and Gynecology, Medical College of Virginia, Virginia Commonwealth University Health System, 23298-0034, 1101 East Marshall Street, Richmond, VA, USA

    Cecelia H. Boardman

  4. Department of Biochemistry and Nutrition, University of Puerto Rico, Medical Sciences Campus, School of Medicine, 00936-5067, San Juan, PR, USA

    Elsa M. Cora

  5. Department of Family Practice, Lexington Clinic, 40504, 1221 South Broadway, Lexington, KY, USA

    Marites C. Buenafe

  6. Department of Preventive Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University’s Feinberg School of Medicine, 60611, 680 North Lake Shore Drive, Suite 1102, Chicago, IL, USA

    Dachao Liu & Alfred Rademaker

  7. Department of Obstetrics and Gynecology, New York University School of Medicine, 10016, 550 First Avenue, TH 528, New York, NY, USA

    David A. Fishman

  8. Department of Gynecologic Surgery/Oncology, Mayo Clinic–Rochester, 55905, 200 First Street S.W., Rochester, MN, USA

    Karl C. Podratz

  9. Department of Obstetrics/Gynecology and Reproductive Sciences, Yale University School of Medicine, 06511, 300 George Street, Suite 8100, New Haven, CT, USA

    Jill L. Reiter & Nita J. Maihle

Authors
  1. Andre T. Baron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacqueline M. Lafky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cecelia H. Boardman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elsa M. Cora
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marites C. Buenafe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dachao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alfred Rademaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David A. Fishman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Karl C. Podratz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jill L. Reiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nita J. Maihle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andre T. Baron .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Missouri, Hospital Dr. 1, Columbia, 65212, U.S.A.

    M. Sharon Stack

  2. School of Medicine, New York University, First Ave. 550, New York, 10016, U.S.A.

    David A. Fishman

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Baron, A.T. et al. (2009). Soluble Epidermal Growth Factor Receptor: A Biomarker of Epithelial Ovarian Cancer. In: Stack, M., Fishman, D. (eds) Ovarian Cancer. Cancer Treatment and Research, vol 149. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-98094-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-98094-2_9

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-98093-5

  • Online ISBN: 978-0-387-98094-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation